Perspective - (2025) Volume 14, Issue 1
Received: 01-Feb-2025, Manuscript No. jhoa-25-168484;
Editor assigned: 03-Feb-2025, Pre QC No. P-168484;
Reviewed: 15-Feb-2025, QC No. Q-168484;
Revised: 22-Feb-2025, Manuscript No. R-168484;
Published:
28-Feb-2025
, DOI: 10.37421/2167-1095.2024.14.497
Citation: Dennis, Naimah. “Advances in Hypertension Management: Beyond the Traditional Drug Classes.” J Hypertens 14 (2025): 497.
Copyright: © 2025 Dennis N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
A prominent area of innovation lies in the development of antihypertensive drugs targeting previously underexplored mechanisms. Among them, endothelin receptor antagonists and neprilysin inhibitors have gained traction for their ability to modulate vasoconstrictive and natriuretic pathways. Endothelin-1, a potent vasoconstrictor implicated in vascular dysfunction, is being targeted through selective antagonists, offering promise especially in resistant hypertension. Similarly, neprilysin inhibitors, often used in combination with angiotensin receptor blockers (as in the case of sacubitril/valsartan), show antihypertensive effects while also benefiting heart failure patients. In parallel, drugs modulating the mineralocorticoid receptor, such as finerenone, are being evaluated not only for blood pressure control but also for renal and cardiovascular protection, particularly in diabetic hypertensive populations. These novel agents represent a shift toward integrated care, where comorbidity management and organ protection are central to therapeutic goals. Importantly, the pipeline of new pharmacologic targets underscores the dynamic nature of antihypertensive therapy and its responsiveness to evolving scientific insights [2-3].
Biologic interventions, previously limited to autoimmune or oncological contexts, are now entering the field of hypertension treatment. Recent findings have illuminated the role of inflammation and immune dysregulation in the pathogenesis of hypertension, particularly through the activation of T-cells and pro-inflammatory cytokines. Monoclonal antibodies targeting specific cytokines (e.g., IL-17 or TNF-alpha) have demonstrated blood pressure-lowering effects in preclinical studies and early-phase clinical trials. Furthermore, vaccine-based therapies, such as those targeting components of the renin-angiotensin system (e.g., Angiotensin II vaccines), offer the potential for long-acting blood pressure control through immune-mediated mechanisms. Although these approaches are still in investigational stages, they signal a promising frontier where hypertension could be managed through immunomodulation, reducing the need for daily pharmacotherapy and potentially improving long-term adherence and outcomes. Continued research and cautious optimism surround the translation of these therapies from bench to bedside [4].
Another transformative area in hypertension management is the use of medical devices and digital therapeutics. Renal denervation, a minimally invasive procedure that disrupts sympathetic nerve activity in the renal arteries, has re-emerged with strong evidence supporting its efficacy in drug-resistant hypertension. Early skepticism has been mitigated by improved device technology and better patient selection criteria, leading to sustained reductions in systolic and diastolic BP. Carotid baroreceptor activation therapy, which modulates autonomic function via electrical stimulation, is another innovative intervention gaining attention. Meanwhile, wearable technology and AI-driven mobile health applications are increasingly utilized to support self-monitoring, medication adherence and clinician feedback. Digital therapeutics not only empower patients but also enable personalized, real-time management strategies, which are crucial in a condition like hypertension that often lacks overt symptoms [5].
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar CrossRef Indexed at
Journal of Hypertension: Open Access received 614 citations as per Google Scholar report